0000731766-24-000146.txt : 20240416 0000731766-24-000146.hdr.sgml : 20240416 20240416060151 ACCESSION NUMBER: 0000731766-24-000146 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITEDHEALTH GROUP INC CENTRAL INDEX KEY: 0000731766 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 411321939 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10864 FILM NUMBER: 24846041 BUSINESS ADDRESS: STREET 1: UNITEDHEALTH GROUP CENTER STREET 2: 9900 BREN ROAD EAST CITY: MINNEAPOLIS STATE: MN ZIP: 55343 BUSINESS PHONE: 9529361300 MAIL ADDRESS: STREET 1: 9900 BREN ROAD EAST CITY: MINNETONKA STATE: MN ZIP: 55343 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP/ DATE OF NAME CHANGE: 20000309 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP DATE OF NAME CHANGE: 19920703 8-K 1 unh-20240416.htm 8-K unh-20240416
0000731766false00007317662024-04-162024-04-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————————
FORM 8-K
—————————————
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 16, 2024
—————————————
UNITEDHEALTH GROUP INCORPORATED
(Exact name of registrant as specified in its charter)
—————————————
Delaware1-1086441-1321939
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
UnitedHealth Group Center, 9900 Bren Road East,Minnetonka,Minnesota55343
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (952) 936-1300
N/A
(Former name or former address, if changed since last report.)
—————————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02    Results of Operations and Financial Condition.
On April 16, 2024, UnitedHealth Group Incorporated (the “Company”) issued a press release announcing its first quarter 2024 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
ExhibitDescription
104Cover Page Interactive Data File (formatted as Inline XBRL).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 16, 2024                 
UNITEDHEALTH GROUP INCORPORATED
By: /s/ Kuai H. Leong
Kuai H. Leong
Deputy Corporate Secretary

EX-99.1 2 a2024q1exhibit991.htm EX-99.1 Document

uhglogo.jpg
UnitedHealth Group Reports First Quarter 2024 Results
Revenues of $99.8 Billion Grew Nearly $8 Billion Year Over Year
Earnings Reflect $0.74 per Share of Impacts from Change Healthcare Cyberattack; $0.49 to Support Direct Response Efforts and $0.25 in Business Disruption Impacts
Company has Provided Over $6 Billion in Advance Funding and Interest-Free Loans to Support Care Providers in Need
First Quarter Net Loss of $1.53 Per Share is Due Primarily to Currency Effects of Previously Reported Brazil Sale and the Cyberattack
Adjusted Earnings of $6.91 Per Share Include the $0.25 in Business Disruption Impacts but Exclude Brazil Sale and Direct Response Costs
(April 16, 2024) UnitedHealth Group (NYSE: UNH) reported first quarter 2024 results reflecting broad-based growth at Optum and UnitedHealthcare, medical care activity consistent with expectations and the impact of the recent cyberattack on Change Healthcare.
“The core story at UnitedHealth Group remains our colleagues delivering improved experiences for the people we serve and driving balanced growth even while swiftly and effectively addressing the attack on Change Healthcare,” said Andrew Witty, chief executive officer of UnitedHealth Group.
The company continues to make significant progress in restoring the affected Change Healthcare services while providing financial support to impacted health care providers. To date, the company has provided over $6 billion in advance funding and interest-free loans to support care providers in need.
Page 1 of 10



Total cyberattack impacts in the first quarter amounted to $0.74 per share and the company estimates full year 2024 impacts of $1.15 to $1.35 per share. In the first quarter, this included $0.49 per share to support direct response efforts such as the Change Healthcare clearinghouse platform restoration and increased medical care expenditures as the company suspended some care management activities to help care providers with their workflow processes. The company estimates direct response costs of $0.85 to $0.95 per share for full year 2024. Direct response costs are included in net earnings and excluded from adjusted earnings per share. Additionally, Change Healthcare business disruption impacts, reflecting lost revenue and the costs of maintaining full readiness of the affected Change Healthcare services, were $0.25 per share in the first quarter. The company currently estimates $0.30 to $0.40 per share business disruption impact for full year 2024. These business disruption impacts are included in both net earnings and adjusted earnings per share.
As reported previously, the company recorded an approximately $7 billion charge in the quarter due to the sale of its Brazil operations, the majority of which was noncash and due to the cumulative impact of foreign currency translation losses.
The company updated its full year 2024 net earnings outlook to $17.60 to $18.20 per share to reflect the Brazil sale and the estimated direct response costs of the cyberattack. The company maintained its adjusted net earnings outlook of $27.50 to $28.00 per share. This adjusted earnings per share outlook excludes the impacts of the direct response costs and Brazil sale, while including the estimated $0.30 to $0.40 per share of business disruption impacts for the affected Change Healthcare services.
Page 2 of 10




uhglogo.jpg
Quarterly Financial Performance
Three Months Ended
March 31,March 31,March 31,December 31,
2024202420232023
(Adjusted)
Revenues$99.8 billion$99.8 billion$91.9 billion$94.4 billion
Earnings from Operations$7.9 billion$8.5 billion$8.1 billion$7.7 billion
Net Margin(1.4%)6.1%6.1%5.8%
UnitedHealth Group’s first quarter 2024 revenues grew nearly $8 billion year over year to $99.8 billion. First quarter earnings from operations were $7.9 billion, including $872 million in unfavorable cyberattack effects. Adjusted earnings from operations of $8.5 billion include the Change Healthcare business disruption impacts and exclude the cyberattack direct response costs. Growth was led by a strong expansion in the number of people served at Optum and UnitedHealthcare.
The company did not reflect any favorable earnings impacting medical reserve development in the quarter. Out of prudence, due to the potential for the cyberattack to affect claims receipt timing, the company reflected an additional $800 million of claims reserves.
Days claims payable of 47.1 compared to 47.9 in fourth quarter 2023 and 47.8 in first quarter 2023. Within this, the acceleration of payments to care providers and the Brazil sale reduced reported days claims payable by three days. The company’s medical costs payable balance increased $1.6 billion from year-end 2023 to $34 billion. The change was due to a $3 billion increase in the incurred but not yet reported (IBNR) component of this balance in part to prudently accommodate the related ongoing claims receipt assessment, partially offset by a reduction in the fully processed claims component due to accelerated care provider claims payments.
Overall care patterns in the first quarter were consistent with the company’s expectations. The first quarter 2024 medical care ratio at 84.3% included 40 basis points of impact due to accommodations to support care providers. The increase from the prior year 82.2% was due to the previously noted revenue effects of the Medicare funding reductions, considerations driven
Page 3 of 10



by the Change Healthcare cyberattack, including accommodations to support care providers, medical reserve and development effects, and business mix.
The first quarter 2024 operating cost ratio of 14.1% included approximately 30 basis points of impact due to costs incurred to support the company’s direct response efforts. The result compared to 14.8% in 2023, reflecting strong operating cost management, partially offset by continued growth of the services businesses and investments to support growth.
Cash flows from operations from the first quarter 2024 were $1.1 billion and were affected by approximately $3 billion due to the company’s cyberattack response actions, including funding acceleration to care providers, and were additionally impacted due to the timing of public sector cash receipts. The company returned $4.8 billion to shareholders in the first quarter through dividends and share repurchases.
Page 4 of 10



uhclogowithr.jpg
UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.
Quarterly Financial Performance
Three Months Ended
March 31,March 31,March 31,December 31,
2024202420232023
(Adjusted)
Revenues$75.4 billion$75.4 billion$70.5 billion$70.8 billion
Earnings from Operations$4.4 billion$4.6 billion$4.3 billion$3.1 billion
Operating Margin5.8%6.1%6.2%4.4%
UnitedHealthcare first quarter revenues of $75.4 billion increased nearly $5 billion over the prior year reflecting growth in the number of people served domestically. Operating earnings were $4.4 billion and adjusted operating earnings were $4.6 billion.
UnitedHealthcare total domestic consumers served grew by nearly 2 million in the first quarter 2024, led by commercial and senior, offset by expected member attrition in Medicaid due to ongoing eligibility redeterminations. Growth across the UnitedHealthcare portfolio reflects strong customer response to the company’s innovative and affordable benefit offerings.
The number of consumers served with domestic commercial offerings grew in the first quarter 2024 to 29.4 million. This growth reflects recognition among the employer and individual markets of UnitedHealthcare’s diverse and innovative product portfolio that drives affordability and consumer ease.
The total number of people served by the company’s offerings for seniors and people with complex needs grew to 9.4 million. UnitedHealthcare offerings feature product designs tailored to meet the specific needs of people with limited economic resources and who are often underserved. Unique offerings, such as integrated card and simplified transportation offerings, led to a significant increase in member engagement and greater consumer satisfaction.
Page 5 of 10



Total people served by the company’s state-based community offerings moderated to 7.7 million, with the year-over-year change due to the ongoing Medicaid eligibility redetermination process. The UnitedHealthcare team is continuing its comprehensive outreach to help families maintain, reinstate or find other affordable coverage. During the first quarter, UnitedHealthcare was selected to provide expanded care services in Texas and to continue providing services in Virginia and Michigan, with the additional support commencing in 2025.
Page 6 of 10




optumlogoforearningsrelease.jpg
Optum’s health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and improving the consumer experience.
Quarterly Financial Performance
Three Months Ended
March 31,March 31,March 31,December 31,
2024202420232023
(Adjusted)
Revenues$61.1 billion$61.1 billion$54.1 billion$59.5 billion
Earnings from Operations$3.5 billion$3.9 billion$3.7 billion$4.6 billion
Operating Margin5.8%6.4%6.9%7.7%
Optum first quarter revenues of $61 billion grew $7 billion. The growth was led by Optum Health and Optum Rx due to continued strong expansion in the number of people served. Operating earnings were $3.5 billion and adjusted earnings were $3.9 billion. Adjusted operating earnings exclude costs to support the direct Change Healthcare response efforts. Operating earnings and adjusted operating earnings include $279 million in business disruption impacts at Change Healthcare.
Optum Health revenue increased 16% over last year, driven by growth in the number of patients served under value-based care offerings and continued expansion of the types and level of care provided. Operating earnings were $1.9 billion and adjusted operating earnings were $2 billion. Optum Health continued to advance and deepen its clinical support for patients, including those with complex medical needs, through virtual, in-home, and in-clinic engagement.
Optum Insight first quarter operating earnings were $490 million and adjusted operating earnings, which exclude direct response costs, were $715 million. Operating earnings and adjusted operating earnings include the $279 million of Change Healthcare business disruption impacts. The revenue backlog grew by over $2 billion compared to the year ago quarter, bringing backlog to nearly $33 billion, reflecting new health system partnerships.
Page 7 of 10



Optum Rx revenue increased 12% in the first quarter due to growth in serving new customers, expanded relationships with existing clients and continued advancement in the comprehensive scope of pharmacy services offered, including specialty and community-based pharmacies. Adjusted scripts grew to 395 million compared to 378 million last year.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.
Earnings Conference Call
As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a conference call with investors at 8:45 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following the call, a webcast replay will be on the Investor Relations page and at https://uhg.com/Replay through April 30, 2024. This earnings release and the Form 8-K dated April 16, 2024, can also be accessed from the Investor Relations page of the company’s website.
Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and
Page 8 of 10



involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
# # #
Page 9 of 10



Investor Contact:Media Contact:
Zack SopcakEric Hausman
952-936-7215952-936-3963
zack.sopcak@uhg.com
eric.hausman@uhg.com
Page 10 of 10




UNITEDHEALTH GROUP
Earnings Release Schedules and Supplementary Information
Quarter Ended March 31, 2024
                                        
Condensed Consolidated Statements of Operations
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Cash Flows
Revenues by Business - Supplemental Financial Information
Earnings by Business - Supplemental Financial Information
People Served and Performance Metrics - Supplemental Financial Information
Reconciliation of Non-GAAP Financial Measures






UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data; unaudited)
Three Months Ended
March 31,
20242023
Revenues
Premiums$77,988$72,786
Products11,90910,267
Services8,8888,080
Investment and other income1,011798
     Total revenues99,79691,931
Operating costs
Medical costs65,73559,845
Operating costs14,07713,625
Cost of products sold11,0569,405
Depreciation and amortization997970
     Total operating costs91,86583,845
Earnings from operations7,9318,086
Interest expense(844)(754)
Loss on sale of subsidiary(7,086)
Earnings before income taxes17,332
Provision for income taxes(1,222)(1,558)
Net (loss) earnings (1,221)5,774
Earnings attributable to noncontrolling interests(188)(163)
Net (loss) earnings attributable to UnitedHealth Group common shareholders$(1,409)$5,611
Diluted (loss) earnings per share attributable to UnitedHealth Group common shareholders $(1.53)$5.95
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a)(b)$6.91$6.26
Diluted weighted-average common shares outstanding (b)922943
(a)See page 7 for a reconciliation of non-GAAP measures.
(b)Due to the anti-dilutive effect on the calculation of loss per share, the Company excluded 8 million potentially dilutive shares outstanding for the three months ended March 31, 2024. Adjustments to net loss and adjusted earnings per share are calculated using dilutive weighted-average common shares outstanding of 930 for the three months ended March 31, 2024.
1


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions; unaudited)
March 31,
2024
December 31,
2023
Assets
Cash and short-term investments$32,710$29,628
Accounts receivable, net27,19721,276
Other current assets29,03527,533
Total current assets88,94278,437
Long-term investments45,92847,609
Other long-term assets149,340147,674
Total assets$284,210$273,720
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable$34,032$32,395
Short-term borrowings and current maturities of long-term debt9,7874,274
Other current liabilities60,61262,385
Total current liabilities104,43199,054
Long-term debt, less current maturities63,85058,263
Other long-term liabilities19,01117,484
Redeemable noncontrolling interests4,5484,498
Equity92,37094,421
Total liabilities, redeemable noncontrolling interests and equity$284,210$273,720

2


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions; unaudited)
Three Months Ended
March 31,
20242023
Operating Activities
Net (loss) earnings$(1,221)$5,774
Noncash items:
Depreciation and amortization997970
Deferred income taxes and other152(263)
Share-based compensation372362
Loss on sale of subsidiary7,086
Net changes in operating assets and liabilities(6,242)9,484
Cash flows from operating activities1,14416,327
Investing Activities
Sales and maturities of investments, net of purchases (purchases, net of sales and maturities)492(2,319)
Purchases of property, equipment and capitalized software(743)(760)
Cash paid for acquisitions, net(3,006)(7,826)
Other, net(3,083)(115)
Cash flows used for investing activities(6,340)(11,020)
Financing Activities
Common share repurchases(3,072)(2,000)
Dividends paid(1,729)(1,537)
Net change in short-term borrowings and long-term debt11,36412,375
Other, net1,6684,352
Cash flows from financing activities8,23113,190
Effect of exchange rate changes on cash and cash equivalents(48)51
Increase in cash and cash equivalents2,98718,548
Cash and cash equivalents, beginning of period25,42723,365
Cash and cash equivalents, end of period$28,414$41,913
3


UNITEDHEALTH GROUP
REVENUES BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION
(in millions; unaudited)
OptumUnitedHealth
Group
Consolidated (a)
UnitedHealthcareOptum
Health
Optum
Insight
Optum
Rx
Total
Optum (a)
Three Months Ended March 31, 2024
Total revenues$75,357$26,731$4,502$30,835$61,052$99,796
Business disruption impacts - cyberattack (b)$—$—$279$—$279$279
Three Months Ended March 31, 2023
Total revenues$70,468$23,004$4,496$27,418$54,059$91,931
UnitedHealthcare Revenues
(in millions; unaudited)
Employer & Individual (E&I)Total
UnitedHealthcare
DomesticGlobalTotal E&IMedicare &
Retirement
Community &
State
Three Months Ended March 31, 2024
Total revenues$17,839$1,532$19,371$35,486$20,500$75,357
Three Months Ended March 31, 2023
Total revenues$16,544$2,163$18,707$33,006$18,755$70,468
(a)Optum and consolidated revenues for the three months ended March 31, 2024 and 2023 include Optum eliminations of $1,016 and $859; and corporate eliminations of $36,613 and $32,596, respectively.
(b)Amounts represent reduced revenues during the business disruption period.
4


UNITEDHEALTH GROUP
EARNINGS BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION
(in millions, except percentages; unaudited)

OptumUnitedHealth
Group
Consolidated
UnitedHealthcareOptum
Health
Optum
Insight
Optum
Rx
Total
Optum
Three Months Ended March 31, 2024
Earnings from operations$4,395$1,899$490$1,147$3,536$7,931
Direct response costs - cyberattack230(a)138(a)225363593
Adjusted earnings from operations (b)$4,625$2,037$715$1,147$3,899$8,524
Operating margin5.8 %7.1 %10.9 %3.7 %5.8 %7.9 %
Adjusted operating margin (b)6.1 %7.6 %15.9 %3.7 %6.4 %8.5 %
Business disruption impacts - cyberattack (c)$—$—$279$—$279$279
Total cyberattack impacts (d)$230$138$504$—$642$872
Three Months Ended March 31, 2023
Earnings from operations$4,343$1,776$907$1,060$3,743$8,086
Operating margin6.2 %7.7 %20.2 %3.9 %6.9 %8.8 %
(a)Amounts primarily represent incremental medical costs for accommodations to support care providers.
(b)See page 7 for description of non-GAAP measures.
(c)Amounts represent reduced revenues during the business disruption period. These amounts are not included within the adjustment to earnings from operations for the three months ended March 31, 2024.
(d)Amounts represent the total impact of the cyberattack, including cyberattack direct response costs and the business disruption impacts.
5


UNITEDHEALTH GROUP
PEOPLE SERVED AND PERFORMANCE METRICS - SUPPLEMENTAL FINANCIAL INFORMATION
(unaudited)
UnitedHealthcare Customer Profile
(in thousands)
People ServedMarch 31, 2024December 31, 2023March 31, 2023
Commercial - Domestic:
Risk-based8,545 8,115 8,025 
Fee-based20,870 19,200 19,325 
    Total Commercial - Domestic29,415 27,315 27,350 
Medicare Advantage7,760 7,695 7,545 
Medicaid7,680 7,845 8,380 
Medicare Supplement (Standardized)4,325 4,355 4,320 
     Total Community and Senior19,765 19,895 20,245 
     Total UnitedHealthcare - Domestic Medical49,180 47,210 47,595 
Commercial - Global2,295 5,540 5,295 
     Total UnitedHealthcare - Medical51,475 52,750 52,890 
Supplemental Data
     Medicare Part D stand-alone3,085 3,315 3,380 
Optum Performance Metrics
March 31, 2024December 31, 2023March 31, 2023
Optum Health Consumers Served (in millions)104103103
Optum Insight Contract Backlog (in billions)$32.8$32.1$30.7
Optum Rx Quarterly Adjusted Scripts (in millions)395400378

Note: UnitedHealth Group served 149 million unique individuals across all businesses at March 31, 2024.
6


UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
Use of Non-GAAP Financial Measures
Adjusted net earnings per share, adjusted earnings from operations, adjusted operating margin and adjusted net margin are non-GAAP financial measures. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. Adjustments made to these measures are as follows:
Intangible Amortization: Adjusted net earnings per share excludes intangible amortization from the relevant GAAP measure. As amortization fluctuates based on the size and timing of the Company’s acquisition activity, management believes this exclusion presents a more useful comparison of the Company's underlying business performance and trends from period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share.
Loss on Sale of Subsidiary: Adjusted net earnings per share and adjusted net margin excludes the loss on sale of subsidiary. On February 6, 2024, the Company completed the sale of its operations in Brazil. As the loss on sale is not representative of the Company's underlying business performance, management believes the exclusion presents a more useful comparison of the Company's underlying business performance and trends from period to period.
Direct Response Costs - Cyberattack: Adjusted net earnings per share, adjusted earnings from operations, adjusted operating margin and adjusted net margin excludes cyberattack direct response costs. Management believes the exclusion of costs incurred to investigate and remediate the attack, other direct and incremental costs incurred as a result of the cyberattack and incremental costs for accommodations to support care providers presents a more useful comparison of the Company's and its reportable segments' underlying business performance and trends from period to period.
Note: See page 5 for reconciliation of GAAP amounts to adjusted earnings from operations and adjusted operating margin.
7


UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in millions, except per share data; unaudited)
Adjusted Net Earnings Per Share
Three Months Ended
March 31,
Projected Year Ended
December 31,
202420232024
Net (loss) earnings attributable to UnitedHealth Group common shareholders$(1,409)$5,611$16,235 - $16,935
Intangible amortization399388~1,600
Tax effect of intangible amortization(98)(96)(400)
Loss on sale of subsidiary (a)7,086— ~7,100
Direct response costs - cyberattack593— 1,000 - 1,150
Tax effect of direct response costs - cyberattack(141)(235) - (285)
Adjusted net earnings attributable to UnitedHealth Group common shareholders$6,430$5,903$25,400 - $26,000
Diluted (loss) earnings per share (b)$(1.53)$5.95$17.60 - $18.20
Intangible amortization per share0.430.41~1.75
Tax effect of intangible amortization per share(0.10)(0.10)~(0.45)
Loss on sale of subsidiary per share (a)7.62— ~7.65
Direct response costs - cyberattack per share0.641.10 - 1.25
Tax effects of direct response costs - cyberattack per share(0.15)(0.25) - (0.30)
Adjusted diluted earnings per share (b)$6.91$6.26$27.50 - $28.00
Additional Information: Total Cyberattack Impacts
Business disruption impacts (c)$279$—$350 - $450
Tax effect of business disruption impacts (c)(48)(70) - (90)
Business disruption impacts, net of tax (c)$231$—$280 - $360
Business disruption impacts per share (c)$0.25$—$0.30 - $0.40
Total cyberattack impacts (d)$872$—$1,350 - $1,600
Tax effect of total cyberattack impacts (d)(189)(305) - (375)
Total cyberattack impacts, net of tax (d)$683$—$1,045 - $1,225
Total cyberattack impacts per share (d)$0.74$—$1.15 - $1.35

Note: See following page for applicable footnotes.
8


Adjusted Net Margin
Three Months Ended
March 31, 2024
Net loss attributable to UnitedHealth Group common shareholders$(1,409)
Loss on sale of subsidiary (a)7,086
Direct response costs - cyberattack593
Tax effect of direct response costs - cyberattack(141)
Adjusted net earnings attributable to UnitedHealth Group common shareholders for loss on sale and direct response costs$6,129
Net margin attributable to UnitedHealth Group common shareholders(1.4)%
Adjusted net margin attributable to UnitedHealth Group common shareholders for loss on sale and direct response costs6.1 %
(a)There were no tax effects for the loss on sale of subsidiary.
(b)Due to the anti-dilutive effect on the calculation of loss per share, the Company excluded 8 million potentially dilutive shares outstanding for the three months ended March 31, 2024. Adjustments to net loss and adjusted earnings per share are calculated using dilutive weighted-average common shares outstanding of 930 for the three months ended March 31, 2024.
(c)Amounts represent reduced revenues during the business disruption period. These amounts are not included within the adjustment to net earnings for the three months ended March 31, 2024 and the projected year ended December 31, 2024.
(d)Amounts represent the total impact of the cyberattack, including cyberattack direct response costs and the business disruption impacts.
9
EX-101.SCH 3 unh-20240416.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 unh-20240416_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 unh-20240416_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Document Information, Document [Axis] Document Information, Document [Axis] Security Exchange Name Security Exchange Name Document [Domain] Document [Domain] Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Cover [Abstract] City Area Code City Area Code Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Document Period End Date Document Period End Date Document Type Document Type EX-101.PRE 6 unh-20240416_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 optumlogoforearningsrelease.jpg begin 644 optumlogoforearningsrelease.jpg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end GRAPHIC 8 uhclogowithr.jpg begin 644 uhclogowithr.jpg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end GRAPHIC 9 uhglogo.jpg begin 644 uhglogo.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 16, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 16, 2024
Entity Registrant Name UNITEDHEALTH GROUP INCORPORATED
Entity Incorporation, State or Country Code DE
Entity File Number 1-10864
Entity Tax Identification Number 41-1321939
Entity Address, Address Line One UnitedHealth Group Center, 9900 Bren Road East,
Entity Address, City or Town Minnetonka,
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55343
City Area Code 952
Local Phone Number 936-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol UNH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000731766
Amendment Flag false
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.unitedhealthgroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports unh-20240416.htm unh-20240416.xsd unh-20240416_def.xml unh-20240416_lab.xml unh-20240416_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "unh-20240416.htm": { "nsprefix": "unh", "nsuri": "http://www.unitedhealthgroup.com/20240416", "dts": { "inline": { "local": [ "unh-20240416.htm" ] }, "schema": { "local": [ "unh-20240416.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "definitionLink": { "local": [ "unh-20240416_def.xml" ] }, "labelLink": { "local": [ "unh-20240416_lab.xml" ] }, "presentationLink": { "local": [ "unh-20240416_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.unitedhealthgroup.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "unh-20240416.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "unh-20240416.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document [Domain]", "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information, Document [Axis]", "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 19 0000731766-24-000146-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000731766-24-000146-xbrl.zip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

XML 21 unh-20240416_htm.xml IDEA: XBRL DOCUMENT 0000731766 2024-04-16 2024-04-16 0000731766 false 8-K 2024-04-16 UNITEDHEALTH GROUP INCORPORATED DE 1-10864 41-1321939 UnitedHealth Group Center, 9900 Bren Road East, Minnetonka, MN 55343 952 936-1300 false false false false Common Stock, $.01 par value UNH NYSE false